Last reviewed · How we verify
Adipose-derived stromal cells
At a glance
| Generic name | Adipose-derived stromal cells |
|---|---|
| Also known as | ASC's |
| Sponsor | Mayo Clinic |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Procedural pain
- Arthralgia
- Joint swelling
- Joint stiffness
- Post procedural contusion
- Post procedural haematoma
Key clinical trials
- Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells (PHASE1)
- Autologous SVF Therapy for Type 2 Diabetes (NA)
- Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS) (PHASE2)
- Stromal Vascular Fraction (SVF) for Knee Post-Trauma Osteoarthritis (PTOA) (EARLY_PHASE1)
- Bone Marrow Versus Adipose Tissue as a Cell Source for Infiltrative Treatment of Knee Osteoarthritis (NA)
- Tolerance of Intra-articular Injection Autologous Stromal Vascular Fraction for the Treatment of Rhizarthrosis (PHASE2)
- Application of Autologous Stem Cells From Adipose Tissue in the Regeneration of Knee Joint Cartilage (PHASE4)
- ASCs in Recently Diagnosed Non-ischemic Heart Failure (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adipose-derived stromal cells CI brief — competitive landscape report
- Adipose-derived stromal cells updates RSS · CI watch RSS
- Mayo Clinic portfolio CI